Viasys Pulls Together
In under a year and a half, Viasys has transformed itself from a collection of 14 independent device companies to an integrated public company operating in four segments of the hospital market: respiratory, critical care, neurocare, and medical/surgical devices. As the successor to the companies that formerly made up the Thermo Biomedical division of Thermo Electron, it starts out with some unique challenges. It's already a public company with almost $400 million in revenues, so it has to be ever mindful of investors' expectations for growth. But it's virtually a start-up in terms of creating a corporate infrastructure and processes. Perhaps the greatest inherited weakness of Viasys is a lack of product-planning skills; Thermo Biomedical hadn't introduced a new product in seven years. Now Viasys must fill pipeline gaps with products that will appeal to its cost-conscious hospital constituency but still yield higher margins. Its middling size adds to the challenge; it's not big enough to afford a product failure, nor can it compete where financial might and product breadth are advantages. But Viasys believes it can handily apply the speed and maneuverability of a small firm to manufacture and market a large company-style product portfolio.
You may also be interested in...
The name Teleflex barely registers among most device executives and hospital customers, but the company's individual brands, Weck, Pilling, and Rusch, are well-known. Teleflex's greatest challenge lies in finding a middle ground between its niche approach, built on the strong brands of its individual businesses, and the resources available from a larger, coordinated corporate effort. It's an issue of identity: can Teleflex ever be anything other than a collection of strong brands?
Thermo Electron is finally reversing course in its innovative, much talked about, but seldom imitated strategy of spin-offs. With almost two dozen public subsidiaries, most lacking critical mass and adequate liquidity, Thermo's new management is pulling them back in.
As Wright Medical's success suggests, the key for mid-tier companies lies not so much in devising innovative sales and marketing programs for these new customers, but in product planning and portfolio design, crafting the right product line for a more cost-conscious customer, while tapping into those technologically innovative opportunities that still exist.